Karolinska Development
1,608 SEK +2,29 %1 investor følger denne virksomhed
Karolinska Development is a Nordic investment company in the life science sector. The company focuses on identifying medical innovations to create and develop companies that further develop such innovations into differentiated products. Karolinska Development's portfolio consists of a number of companies focused on developing treatment methods for diseases that are classified as life-threatening and serious. The largest business operations are in the Nordic market.
Omsætning
2,3 mio.
EBIT %
-3.800,87 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
KDEV
Daglig lav / høj pris
1,564 / 1,608
SEK
Markedsværdi
280,05 mio. SEK
Aktieomsætning
147,82 t SEK
Volumen
93 t
Finanskalender
Delårsrapport
17.11.2023
Årsrapport
16.02.2024
Delårsrapport
26.04.2024
Generalforsamling
16.05.2024
Delårsrapport
30.08.2024
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| invoX Pharma Ltd | 47,7 % | 43,9 % |
| Worldwide International Investments Ltd | 10,4 % | 9,6 % |
Premium
Not activated
This content is for our Premium customers only.
Viser Alle indholdstyper